Eli Lilly and Company (NYSE:LLY) SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.48 during trading hours on Tuesday, hitting $86.06. The stock had a trading volume of 3,876,686 shares, compared to its average volume of 3,672,667. Eli Lilly and Company has a 52 week low of $66.39 and a 52 week high of $89.09. The firm has a market capitalization of $93,945.43, a price-to-earnings ratio of 20.86, a PEG ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 earnings per share. analysts predict that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.42%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

Several analysts have weighed in on LLY shares. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Leerink Swann upped their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their price objective for the stock from $84.23 to $88.00 in a report on Tuesday, October 10th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $90.25.

Institutional investors and hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new stake in Eli Lilly and in the 3rd quarter valued at approximately $916,000. Public Employees Retirement System of Ohio raised its position in Eli Lilly and by 0.4% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 684,533 shares of the company’s stock valued at $58,555,000 after buying an additional 2,452 shares during the last quarter. Garde Capital Inc. acquired a new stake in Eli Lilly and in the 3rd quarter valued at approximately $202,000. Archford Capital Strategies LLC raised its position in Eli Lilly and by 26.2% in the 3rd quarter. Archford Capital Strategies LLC now owns 8,076 shares of the company’s stock valued at $690,000 after buying an additional 1,676 shares during the last quarter. Finally, Salem Investment Counselors Inc. raised its position in Eli Lilly and by 7.5% in the 3rd quarter. Salem Investment Counselors Inc. now owns 48,460 shares of the company’s stock valued at $4,173,000 after buying an additional 3,400 shares during the last quarter. Hedge funds and other institutional investors own 76.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/05/eli-lilly-and-company-lly-svp-sells-3152895-30-in-stock.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.